Searchable abstracts of presentations at key conferences in endocrinology

ea0034p359 | Steroids | SFEBES2014

Does recurrent hypoglycaemia, a known activator of the HPA axis, alter the diurnal pattern of cortisol release?

George Priya , Mackie Alasdair , Connell John , McCrimmon Rory

In population studies, premature cardiovascular disease is associated with cortisol dysregulation. Recently, recurrent hypoglycaemia in individuals with type 1 diabetes (T1D) was reported to be associated with increase carotid intima–media thickness. Hypoglycaemia is a potent activator of the hypothalamo-pituitary–adrenal axis (HPA axis) with eventual release of cortisol. We hypothesized that individuals with T1D who experience recurrent hypoglycaemia might demonstra...

ea0028p215 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2012

Investigation and Management of Primary Aldosteronism - A Review of Cases and Audit of Outcomes in a Tertiary Referral Centre

Currie Gemma , O'Dwyer Patrick , Connell John , Freel Marie

Primary aldosteronism (PA) accounts for up to 15% of cases of hypertension, and associates with increased cardiovascular morbidity. Specific treatment options include mineralocorticoid antagonists or adrenalectomy; the latter offers cure although reported rates vary between 20–60%. The role of adrenal vein sampling (AVS) in diagnosing PA remains controversial. By reviewing casenotes of PA patients treated surgically and comparing with matched medically managed PA patients...

ea0025oc2.3 | Steroids | SFEBES2011

APEX1, a novel, negative regulator of aldosterone synthase activity, differentially binds to a single nucleotide polymorphism in the aldosterone synthase gene and represses transcriptional activity both in vitro and in vivo

McManus Frances , Sands William , Fraser Robert , Davies Eleanor , Connell John

Aldosterone synthesis is heritable; a single nucleotide polymorphism (SNP) in the promoter of the aldosterone synthase gene (position −344, rs1799998) has been associated with an increased plasma aldosterone levels and hypertension. However, deletion of this site has no effect on gene transcription in vitro and therefore the mechanism that links genotype with phenotype is unclear.We identified a polymorphism at position −1651 T/C (rs13...

ea0021p359 | Steroids | SFEBES2009

Variation in the aldosterone synthase gene may alter gene transcription via altered transcription factor binding

McManus Frances , Sands William , Davies Eleanor , Connell John

The aldosterone synthase gene encodes the final step in the production of aldosterone. The aldoststerone synthase gene is polymorphic and variants within the gene and the regulatory region have been associated with hypertension and a phenotype of relatively higher level of aldosterone and its metabolites. However to date; none of the polymorphisms in the regulatory region of CYP11B2 have been shown to alter transcription. Seven novel polymorphisms in the promoter region of CYP...

ea0013oc1 | Steroid synthesis and action | SFEBES2007

Monogenic polycystic ovary syndrome (PCOS) due to novel mutations in the H6PD gene - apparent cortisone reductase deficiency (ACRD)

Slabbert Ana , Lavery Gareth , Connell John , Walker Elizabeth , Stewart Paul

ACRD presents with clinical features of hyperandrogenism in females similar to those of PCOS (acne, hirsutism, oligomenorrhea, infertility), and precocious puberty in males. Obesity also occurs in some cases. Increased cortisol clearance leads to an increased hypothalamic-pituitary-adrenal axis drive resulting in elevated serum androgen levels and a decreased urinary cortisol metabolite: cortisone metabolite ratio below 0.5 (normal adult range 0.7–1.3). These observations...

ea0011p375 | Diabetes, metabolism and cardiovascular | ECE2006

The acute stimulation of nitric oxide synthesis by rosiglitazone in human aortic endothelial cells is independent of the PPAR gamma receptor but is dependant on the fuel sensing enzyme AMPK

Boyle JG , Salt IP , Cleland SJ , Connell JMC

The PROactive study recently demonstrated that pioglitazone, a thiazolidinedione class drug, reduces macrovascular morbidity and mortality in patients with type 2 diabetes. This class of drug has been reported to exert PPAR gamma receptor dependent as well as receptor independent effects, possibly via AMP kinase activation (AMPK) but the precise mode of action resulting in improved cardiovascular outcome remains uncertain.We studied the effects of rosigl...

ea0011p378 | Diabetes, metabolism and cardiovascular | ECE2006

SiRNA-mediated depletion of synaptotagmin-11 abrogates insulin-stimulated glucose uptake in 3T3-L1 adipocytes

Miller SCM , Mitra P , Connell JMC , Gould GW

The fusion of insulin-stimulated GLUT4-containing vesicles (GSV) with the plasma membrane (PM) of adipose or skeletal muscle cells is governed by regulated exocytosis. In all such membrane fusion events cognate t- and v-SNAREs interact in an ordered way to allow vesicles to first dock with, and then fuse with the plasmalemma. In neurons, the best-studied example of this well conserved process, the protein species responsible for directing the final (rate-limiting) fusion step ...

ea0011p568 | Growth and development | ECE2006

Growth hormone induced improvement in quality of life does not correlate with reduction in vascular risk in adult hypopituitary patients

McCallum RW , Petrie JR , Dominiczak AF , Connell JMC

Hypopituitary patients on conventional hormone replacement, excluding GH have a reduced quality of life (QoL) and an increased risk of cardiovascular mortality. NICE guidelines on criteria for initiation and maintenance of therapy rely on QoL score defined by the Adult GHD assessment (AGHDA) questionnaire. However, it is uncertain how this score is related to other biological effects such as vascular risk.Methods: Sixteen hypopituitary patients were recr...

ea0009p32 | Diabetes and metabolism | BES2005

Rosiglitazone and phenformin, but not metformin activate AMP-activated protein kinase and stimulate nitric oxide release in human aortic endothelial cells

Boyle J , Cleland S , Salt I , Connell J

Thiazolidinediones and biguanides improve insulin resistance and are used in the management of type 2 diabetes. Use of biguanides is associated with a reduction in vascular complications in patients with diabetes. Pre-clinical studies with thiazolidinediones suggest improvements in vascular function and long-term clinical trials in type 2 diabetes are in progress. These effects are proposed to be mediated through inhibition of complex 1 in the mitochondrial respiratory chain a...

ea0007p141 | Growth and development | BES2004

Growth hormone replacement reduces circulating inflammatory markers, blood pressure and large artery compliance but does not affect resistance artery function in adult hypopituitary patients

McCallum R , Spiers A , Sattar N , Petrie J , Dominiczak A , Connell J

Hypopituitary patients receiving conventional hormonal therapy, excluding Growth Hormone, have an increased risk of vascular mortality. Significant endothelial dysfunction with impaired aortic distensibility has been demonstrated in these patients with some improvement in arterial stiffness after GH therapy. Inflammation is central in the pathophysiology of atherosclerosis and C-reactive protein is a validated marker for predicting cardiovascular risk.Fo...